Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 and Diltiazem DDI Study
NCT06554639Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area under the concentration versus time curve from 0 to infinity, Area under the concentration versus time curve from 0 to last quantifiable sample and 6 more. Started Jul 2024; status: completed.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06554639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554639.